Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma
A non-interventional, multicenter, prospective trial
Recent publication
In BRAF V600-mutated melanoma, the efficacy of the combination of dabrafenib and trametinib has been confirmed in phase 3 clinical trials. Patients with unresectable and/or metastatic melanoma were not included in these studies and there was a lack of knowledge about the efficacy and safety of dabrafenib plus trametinib in this subgroup. In a non-interventional, real-life study, physicians from different Austrian hospitals analysed the data of 79 patients with unresectable and/or metastatic melanoma to fill this knowledge gap. The results are published in the journal Melanoma Research (Open Access). The Clinical Division of Dermatology and Venereal Diseases at the University Hospital St. Pölten was involved in the study.
Richtig E, Nguyen VA, Koelblinger P, Wolf I, Kehrer H, Saxinger W et al. Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial. Melanoma Research. 2023 Dec 13. Epub 2023 Dec 13. doi: 10.1097/CMR.0000000000000948
PD Dr. Christine Hafner
Division of Dermatology and Venereal Diseases (University Hospital St. Pölten)
Dr. Elisabeth Jecel-Grill
Division of Dermatology and Venereal Diseases (University Hospital St. Pölten)
